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Abstract
Background: The diabetogenic action of statins remains a concern, particularly in patients at high risk for diabetes
receiving intensive statin therapy. Despite the risk of diabetes with statin use being considered a potential class
effect, recent studies have suggested that pitavastatin exerts neutral or favorable effects on diabetogenicity. However,
no randomized trial has compared the long-term effects of pitavastatin with those of other statins on glycemic control
in populations at high risk for diabetes. Hence, we aim to assess the long-term effects of pitavastatin in comparison
with atorvastatin on glucose metabolism in patients with metabolic syndrome (MetS).
Methods/design: The Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin
in patients with Metabolic syndrome (LESS-DM) trial is a prospective, randomized, open-label, active control clinical trial
of patients with MetS. We plan to randomize 500 patients with MetS (1:1) to receive high-dose pitavastatin (4 mg) or
atorvastatin (20 mg) daily for 24 months. The primary endpoint will be the change in hemoglobin A1c after
statin treatment. Secondary endpoints will include the following: (1) changes in biochemical markers, including insulin,
C-peptide, homeostasis model assessment of insulin resistance and insulin secretion, and adiponectin; (2) changes in
imaging parameters, including carotid elasticity metrics and indices of cardiac function; and (3) the incidence of clinical
events, including new-onset diabetes and cardiovascular disease.
Discussion: In this trial, we will explore whether pitavastatin 4 mg does not disturb glucose metabolism in patients
with MetS. It will also provide mechanistic information on statin type-dependent diabetogenic effects and surrogate
data regarding vascular and cardiac changes achieved by intensive statin therapy.
Trial registration: ClinicalTrials.gov, NCT02940366. Registered on 19 October 2016.
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Background
Statins are powerful cholesterol-lowering drugs that
can reduce morbidity and mortality. On the basis of
these prognostic benefits, statins have been the main-
stay of treatment for atherosclerotic cardiovascular
disease (CVD) [1]. Furthermore, there is mounting
evidence that statins can exert beneficial cardiovascu-
lar pleiotropic effects beyond their lipid-lowering
actions [2]. However, there have been persistent concerns
regarding the diabetogenic property of statins. In fact,
several meta-analyses have demonstrated that statin
treatment is associated with a 10–12% increased risk
of new-onset diabetes mellitus (NOD) [3, 4]. Notably,
this risk is further increased in patients treated with
intensive statin regimens [5] and in subjects with
preexisting risk factors for NOD [6]. In this regard,
although the implications of statin-induced diabetes
on the long-term outcomes are uncertain, statin-
treated patients at high risk of developing NOD
should be monitored regularly for changes in plasma
glucose or hemoglobin A1c [7], especially when the
patients are on intensive statin treatment. However,
there are no randomized clinical trials addressing this
problem.
An alternative strategy to mitigate the potential risk
of statin-induced diabetes might include the use of
less diabetogenic statins. Although whether the diabe-
togenic action of statins is a class effect remains
controversial, recent studies have demonstrated that
pitavastatin use might be associated with neutral, or
even favorable, effects on glucose metabolism [8, 9].
However, an important limitation of these studies is their
short follow-up duration. Furthermore, the underlying
mechanism is poorly understood, although researchers in
some studies have reported the possibility that
adiponectin is associated with the effect of statins on the
risk of NOD [10, 11].
Thus, the purpose of the present study, the Long-
term Effects of high-doSe pitavaStatin on Diabeto-
genicity in comparison with atorvastatin in patients
with Metabolic syndrome (LESS-DM) trial, is to
investigate the long-term effect of pitavastatin on
glucose metabolism in comparison with atorvastatin
in patients with metabolic syndrome (MetS), a group
at high risk for developing NOD. In this study, we
also aim to evaluate changes in adiponectin to
provide insight into the relevant mechanisms leading
to statin-induced diabetes. Additionally, measure-
ments of carotid elasticity and cardiac function by
using carotid ultrasound and echocardiography,
respectively, will be provided as surrogate imaging
endpoints to compare the potential benefits of
pitavastatin versus atorvastatin on the cardiovascular
system before the clinical endpoint data can be
obtained [12, 13].
Methods/design
Study rationale and objectives
This trial is a prospective, multicenter, randomized,
open-label, active control study. The purpose of the
study is to assess the effect of pitavastatin 4 mg daily
versus atorvastatin 20 mg daily on changes in various
parameters reflecting glucose metabolism in patients with
MetS after 24 months of treatment. The time line of the
study is illustrated in Fig. 1. The Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist and figure are given in Additional file 1 and Fig. 2,
respectively. The trial protocol is registered with Clinical
Trials.gov (NCT02940366).
Fig. 1 Study design of the Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients
with Metabolic syndrome (LESS-DM) trial
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Study participants
We will recruit from patients with MetS of both
genders, aged 21 years or older, and who are candidates
for statin therapy for prevention against CVD who visit
outpatient clinics. These patients with MetS will be
eligible only when they have no evidence of diabetes at
baseline. Diabetes mellitus will be diagnosed as a
random plasma glucose level ≥ 200 mg/dl along with
classic symptoms of hyperglycemia, fasting plasma
glucose level ≥ 126 mg/dl, 2-h postprandial plasma glucose
level ≥ 200 mg/dl, and/or hemoglobin A1c ≥ 6.5%, or if a
patient is taking medication for diabetes [14]. MetS will be
defined according to the National Cholesterol Education
Program Adult Treatment Panel III criteria [15]. The
definition for anthropometric cutoff points of abdominal
obesity will be based on the International Obesity Task
Force criteria for the Asia-Pacific population [16]. The
indication for statin therapy will be defined on the basis of
the current guidelines [1]. Subjects fulfilling at least one of
the following exclusion criteria will not be eligible for this
study: (1) history of acute coronary syndrome or cerebro-
vascular disease in the past 2 months; (2) history of statin
exposure within the past 1 month; (3) any anticipated
change in statin regimen; (4) active malignancy; (5) chole-
stasis (serum total bilirubin > 3 mg/dl) or active liver
disease (serum alanine transaminase > 200 IU/L); (6)
chronic renal failure (serum creatinine > 2 mg/dl); (7)
failure to obtain informed consent; (8) difficulty in
completing follow-up; (9) concomitant use of
medications affecting glucose metabolism, such as
steroids and atypical antipsychotics; (10) known
allergy to statins; and (11) any contraindication to
statin therapy, including pregnancy/potential preg-
nancy, breastfeeding, cyclosporine use, myopathy, or
genetic disorders.
Randomization
After the screening phase, randomization will be
performed by using a web-based computerized program
hosted at the Medical Research Collaborating Center of
Seoul National University Hospital. With this program,
eligible participants will be randomly allocated in a 1:1
ratio to receive either pitavastatin or atorvastatin. To
ensure balance of the treatment groups with respect to
gender, a randomization scheme will be performed
separately within the stratum of gender. Stratified
randomization according to previous use of statins will
also be conducted to ensure even distribution of this
factor between the study groups.
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure
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Interventions
The trial will be conducted for 24 months. After
randomization, the study participants will take pitavasta-
tin 4 mg or atorvastatin 20 mg once daily. The prescrip-
tion and administration of the study medications will be
performed in an open-label manner. The dose of
pitavastatin was set on the basis of a previous study in
which researchers reported the effect of high-dose pita-
vastatin on glucose homeostasis [8]. Atorvastatin was
chosen as the active control because it is the most com-
monly used statin and has been reported to result in an
increase in insulin resistance and ambient glycemia [17].
The dose of atorvastatin was selected on the basis of
previous experiments comparing these two statins [18,
19]. The investigators and clinical research coordinators
will assess the drug compliance of the study participants,
and those with < 70% compliance will be excluded from
the per-protocol analysis. In addition to medical inter-
ventions, lifestyle modifications will be encouraged as
background therapy in this study. On the basis of previ-
ous studies, the patients’ smoking status, alcohol con-
sumption, diet, and level of physical activity are
considered major modifiable lifestyle factors [20, 21].
Thus, the patients will be instructed and encouraged to
adhere to healthy lifestyles, including not smoking, no
excessive alcohol consumption, low-risk diets, and being
physically active.
Measurements
Data on the patients’ medical history, physical examin-
ation findings, vital signs, anthropometric measures,
blood biochemical tests, and imaging parameters will be
collected by trained staff at our institution. Weight and
height will be measured by trained nurses, and body
mass index will be calculated as the weight in kilograms
divided by height in meters squared. Body composition
will be assessed using a multifrequency bioimpedance
analyzer (InBody 720; InBody, Seoul, Korea) [22].
The primary endpoint of this study is the change in
hemoglobin A1c after 24 months of statin treatment.
The secondary endpoints include changes in other
laboratory variables, such as insulin, C-peptide, the insulin
resistance index of the homeostasis model assessment, the
insulin secretory ability index of the homeostasis model
assessment, lipid profiles (including total cholesterol,
triglycerides, high-density lipoprotein cholesterol, and
low-density lipoprotein cholesterol), adiponectin, C-
reactive peptide, and troponin I, after 24 months of statin
treatment. Carotid ultrasound and echocardiography will
be performed at baseline and after 12 and 24 months of
therapy to obtain data on carotid elasticity and cardiac
function, respectively. Specifically, the carotid elasticity
metrics, including strain, stiffness, and distensibility by the
B-mode and speckle-tracking methods, will be measured
as described previously [23]. The imaging parameters
of cardiac function to be measured include the left
ventricular global longitudinal strain by speckle-
tracking echocardiography as well as traditional indi-
ces derived from two-dimensional, Doppler, and tissue
Doppler echocardiography [24]. Additional file 2
provides a detailed description of the methods that
will be used to measure the carotid ultrasound and
echocardiographic parameters.
In addition, the incidences of NOD and CVD, includ-
ing coronary heart disease (angina, myocardial infarc-
tion, cardiac revascularization, or coronary death),
stroke (fatal or nonfatal ischemic stroke), heart failure,
arrhythmia, peripheral vascular disease, and venous
thromboembolism, will be assessed during the follow-up
of this trial. Follow-up of these clinical events will be
performed by means of in-office visits, medical record
review, and telephone contact. Specifically, trained
research personnel who are unaware of the study group
assignments will review all medical records and will also
conduct telephone interviews if needed to monitor the
development of clinical events. The schedule for the
assessments is summarized in Table 1.
Laboratory investigations
Venipuncture will be performed on the median cubital
vein of participants, and blood samples will be collected
into evacuated tubes by using aseptic precautions. Urine
samples will also be drawn into standard urine collection
containers. All biochemical analyses, except adiponectin,
will be performed in the Seoul National University
Hospital Department of Laboratory Medicine, a fully
accredited diagnostic laboratory. Specifically, the depart-
ment of laboratory medicine of our institute is accre-
dited by the College of American Pathologists (CAP)
and has been inspected every 2 years since 2012. The
proficiency testing offered by CAP has been performed
for all laboratory assays, including hemoglobin A1c.
With regard to the details of hemoglobin A1c measure-
ment, venous blood samples collected in ethylenedi-
aminetetraacetic acid bottles will be transported
immediately from outpatient clinics to the department
of laboratory medicine. Then, hemoglobin A1c will be
measured using ion exchange high-performance liquid
chromatography (VARIANT II TURBO 2.0 system;
Bio-Rad Laboratories, Hercules, CA, USA). Patients
will be requested to be fasting for > 10 h prior to the
test, although hemoglobin A1c values reflect the aver-
age glucose level over the last several weeks. The
within-laboratory coefficients of variation for the
hemoglobin A1c assay are 1.26% for the normal quality
control material and 0.85% for the high quality control
material, respectively, representing excellent within-
laboratory replication. Analysis of adiponectin will be
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performed at GreenCross LabCell Corp. (Yongin,
Korea), an established diagnostic laboratory certified by
the key domestic and international accreditation bodies,
including CAP. Adiponectin will be measured by
enzyme-linked immunosorbent assay (ELISA) (Human
Adiponectin ELISA, BioVendor, Brno, Czech Republic;
VersaMax ELISA Microplate Reader, Molecular
Devices, Sunnyvale, CA, USA). Samples will be stored
at −70 °C because the analysis of adiponectin will be
performed as a batch, whereas other biochemical
analyses will be conducted as patients present.
Trial organization
The executive committee, composed of the study chair-
person and selected members among the investigators,
will govern all aspects of the LESS-DM trial. This
committee will also be responsible for reviewing the final
results, determining the methods of dissemination, and
preparing the subsequent publications. Data coordin-
ation will be conducted at the Cardiovascular Center of
Seoul National University Hospital. The data and safety
monitoring board, composed of cardiologists and a
biostatistician, will be responsible for making












Medical history √ √ √ √ √
Physical examination √ √ √ √ √
Vital signs √ √ √ √ √
Anthropometric measures √ √ √
Blood tests
Complete blood count √ √
Routine blood chemistry √ √ √
Lipid profile √ √ √
Fasting plasma glucose √ √ √
Hemoglobin A1c √ √ √
Insulin √ √ √
C-peptide √ √ √
HOMA-R √ √ √
HOMA-β √ √ √
Adiponectin √ √ √
High-sensitivity CRP √ √
Cardiac troponin I √ √
Creatine kinase √ √ √
Carotid ultrasound
Strain by B-mode √ √ √
Stiffness by B-mode √ √ √
Distensibility by B-mode √ √ √
Strain by speckle tracking √ √ √
Stiffness by speckle tracking √ √ √
Echocardiography
2D measurements √ √ √
M-mode parameters √ √ √
Doppler parameters √ √ √
Tissue Doppler parameters √ √ √
2D speckle-tracking analysis √ √ √
Clinical events √ √ √ √ √
Abbreviations: HOMA-R Insulin resistance index of homeostasis model assessment, HOMA-β Secretory ability of homeostasis model assessment, CRP C-reactive
protein, 2D Two-dimensional
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recommendations on any issue related to the safety or
compliance of the patients throughout the course of the
trial. This board will be able to recommend that the ex-
ecutive committee stop the study prematurely or modify
the study protocol, although all final decisions regarding
these issues will rest with the executive committee. The
study sponsor, JW Pharmaceutical Corporation (Seoul,
Korea), will only provide funding for this trial and will
not have access to the study results until the final
analyses are completed.
Data and safety monitoring plan
The investigators and clinical research coordinators will
regularly monitor all parts of the trial, including the
enrollment status, medical records, case report forms, and
compliance with the study protocol, during the study
period. For safety evaluation, adverse events will be
assessed and reported during each patient visit. All serious
adverse events will be reported to the investigators and
the ethics committee.
Personal data protection and confidentiality
Confidentiality will be maintained throughout the trial
by assigning all participants with a unique identification
code. In order to protect participants’ anonymity, their
names will not be used. The files containing the personal
details of the participants along with their identifier
codes will be stored separately in a locked filing
cabinet and will be accessible only to the principal
investigator. All data will be kept for a maximum of
3 years from the date of completion of this study and
then destroyed securely.
Sample size
The sample size was calculated by assuming an expected
difference of 0.2% in hemoglobin A1c change between
the groups and a population variance of 0.5%, based on
previous studies [25, 26]. Thus, with a power of 95%, a
two-tailed α of 5%, and a presumed dropout rate of
10%, a sample of 250 patients in each group will be
sufficient to detect this difference. Accordingly, a total
of 500 participants will be randomized and included
in our analysis.
Statistical analyses
The statistical analyses will be performed on both
intention-to-treat and per-protocol bases. The intention-
to-treat analyses will include all randomized participants
who provide written informed consent, regardless of
whether the study treatment is administered correctly.
The per-protocol analyses will include all study partici-
pants who complete the trial with an adequate adminis-
tration of the study drug (≥70% of the planned doses)
and without any major protocol violations. Major
protocol violations include inappropriate enrollment,
the use of a prohibited concomitant medication, a
violation of the dose or schedule of drug administra-
tion, or any other violation considered to be a major
violation. The main analyses will be performed on an
intention-to-treat basis.
The values will be expressed as the mean ± SD or me-
dian (IQR), as appropriate. Comparisons of continuous
and categorical data will be made by Student’s t test and
the chi-square test, respectively. The difference in
changes between the groups will be analyzed using both
Student’s t test and analysis of covariance to adjust for
the baseline values. Two-sided p values < 0.05 will be
considered statistically significant. All analyses will be
performed using IBM SPSS version 22.0 software (IBM,
Armonk, NY, USA).
Discussion
The risk of statin-induced diabetes has been found to be
increased in patients receiving an intensive statin regi-
men and in patients with known risk factors for NOD
[5, 6]. Hence, patients at high risk for developing NOD,
such as patients with MetS, should be monitored
carefully, particularly when high-intensity statin therapy
is used. Alternatively, selective use of statins with favor-
able effects on glucose metabolism may represent a
feasible and safe strategy for managing these patients.
Given recent reports indicating neutral or beneficial
effects of pitavastatin on glucose metabolism [8, 9], pita-
vastatin is suggested as the preferred agent. However,
the current clinical guidelines do not recommend a
specific statin type in populations at high risk for devel-
oping NOD [1, 27], owing to the limited data available.
Specifically, most previous studies had a fixed follow-up
period of 12 weeks [7, 9], allowing only for assessment
of the short-term effects of statins on glucose metabol-
ism. More importantly, to date, there have been no
clinical trials specifically designed to investigate the
diabetogenic effects of statins. In this regard, a random-
ized trial with longer follow-up is warranted, considering
that the long-term effect of statins on diabetes risk is a
more clinically relevant endpoint. The LESS-DM trial will
provide data on whether long-term use of pitavastatin
(24 months), in comparison with atorvastatin (a represen-
tative diabetogenic statin), results in protective or deleteri-
ous effects on several parameters related to glucose
metabolism in the setting of MetS. Thus, the findings of
the LESS-DM trial will not only confirm or refute the
previous observations regarding the favorable effects of
pitavastatin on glucose metabolism but also extend
knowledge about the long-term effects of intensive statin
treatment on NOD.
Patients with MetS seem to represent a potential
target population in which diabetogenic statin use is of
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particular concern, given that MetS is a constellation of
interrelated risk factors for not only CVD but also
diabetes [28, 29]. Because preventive strategies for CVD
have been found to be clinically effective and cost-
effective in general high-risk populations, the import-
ance of integrating CVD prevention efforts has also been
underscored as a cornerstone for improving the progno-
sis in patients with MetS [30, 31]. Although lifestyle
modification is the standard first-line means of prevent-
ing CVD in these patients, this is usually not enough to
reach the goal recommended in general clinical practice.
Pharmacological intervention using various medications
is considered an alternative and practical approach for
the primary prevention of CVD. Among the currently
available pharmacological agents, statins have been
suggested to exert protective effects against CVD develop-
ment in patients with MetS [30, 32]. Specifically, several
post hoc analyses of clinical trials testing simvastatin, lova-
statin, atorvastatin, or rosuvastatin for primary or second-
ary CVD prevention have shown that statin therapy offers
significant benefits to both the subgroup of patients with
MetS and the entire study population [33]. However,
although the primary consideration when pharmacological
interventions are contemplated for patients with MetS is
the prevention of CVD, the influence of these agents on
diabetes risk should also be taken into account, owing to
the high risk of developing NOD in this population. In
particular, there is a concern that the use of statins with
diabetogenic properties may reduce the potential net
benefits of statin therapy in these patients. Indeed,
researchers in previous studies have reported that atorva-
statin or rosuvastatin therapy is associated with a greater
risk of NOD in patients with MetS than in those without
[34, 35]. Thus, while the clinical benefits of statin therapy
fortunately exceed the hazard of developing diabetes, even
in patients with MetS [35], the magnitude of the net bene-
fit might be attenuated with the use of more diabetogenic
statin types and therefore could theoretically be enhanced
further with the use of less diabetogenic ones. However,
there have been no previous studies assessing whether sta-
tins with less diabetogenic properties have greater benefi-
cial effects on the cardiovascular system, particularly in
individuals at high risk for diabetes, including patients
with MetS. In this context, we plan to prospectively test
the hypothesis that the difference in diabetogenicity
between the two statin types may contribute to differences
in their impacts on cardiac and vascular functions. Among
several imaging parameters reflecting cardiac and vascular
functions, we plan to measure left ventricular myocardial
strain and carotid artery elasticity metrics in light of previ-
ous studies demonstrating the positive effect of statin use
on left ventricular function [36] and carotid artery elasti-
city [12]. Moreover, because left ventricular myocardial
strain and carotid artery elasticity metrics have been found
to have prognostic values in predicting adverse clinical
outcomes [37–40], it is tempting to speculate that studies
comparing effects of different statins (with different diabe-
togenic properties) on these imaging parameters may pro-
vide useful information for inferring the potential benefits
of using less-diabetogenic statins on cardiovascular out-
comes until clinical endpoint data become available.
Hence, the results of the LESS-DM trial will provide intri-
guing insight into the long-term consequences of statin-
induced diabetes. Ultimately, we consider that our
findings may help clinicians in selecting the most ap-
propriate statin type for long-term treatment of
patients with MetS.
Further, adiponectin has gained increasing recognition
as an important antidiabetic hormone derived from
adipose tissue [10, 41, 42]. Thus, the investigation of the
link between statins and adiponectin may help to eluci-
date the molecular mechanisms underlying statin-
induced diabetes. Several previous studies, albeit
conducted in small numbers of patients, have demon-
strated that the effects of statins on adiponectin differ
according to the type of statin used [10]. Of note, in
these studies, increases in the plasma adiponectin levels
were relatively consistent and almost exclusively
observed in patients receiving pitavastatin [43–45],
whereas the adiponectin levels were unchanged or even
decreased in those treated with other statin types,
including atorvastatin [17, 46–48]. These findings sug-
gest that the adiponectin-increasing effect of pitavastatin
might be causally related to its neutral or favorable
impact on glucose metabolism. The LESS-DM trial
results will shed light on the potential link between the
statin type and diabetogenicity by assessing the continuous
changes in the adiponectin levels and the relationship
between these changes and several glucose metabolism
parameters. Considering that hypoadiponectinemia is a
main contributor to MetS [49–51], patients with MetS are
an appropriate study population for assessing the
adiponectin-increasing effect of statins. Additionally, some
studies have suggested that adiponectin per se may be pro-
tective against arterial stiffness [52, 53] and left ventricular
systolic dysfunction [54, 55]. Taken together, it can be
speculated that the use of statins with positive effects on
the adiponectin level might have more beneficial impacts
on the vascular and cardiac functions in patients with
MetS, as compared with other statins, a hypothesis that
will be tested in this trial.
Strengths and weaknesses
To date, there have been few head-to-head trials
comparing the effects of different statins on glucose
metabolism. Therefore, our study has an advantage in this
respect because we will directly compare the effect of pita-
vastatin with that of atorvastatin, one of the most widely
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used statins clinically, on glucose metabolism and NOD.
Another strength of this study is the provision of informa-
tion regarding the impact of statins on adiponectin, which
may give insight into the potential mechanisms underlying
the difference in diabetogenic properties according to the
statin type. This study also has an advantage in that it will
include analyses of the effects of statin therapy on imaging
surrogate markers, such as carotid elasticity metrics and
echocardiographic parameters. On one hand, the results
of these analyses will address the question whether the
use of less-diabetogenic statin types has more beneficial
effects on vascular and cardiac functions in patients at
high risk for diabetes. On the other hand, the major limi-
tation of our study is that the sample size is relatively
small to detect differences in clinical outcomes, such as
NOD or cardiovascular events, between the groups. To
mitigate this limitation, we plan to use imaging surrogate
endpoints, which may allow for a smaller sample size and
a shorter study duration than clinical endpoints and
thereby enable the assessment of the potential benefits of
pitavastatin on cardiovascular outcomes. However, we
should acknowledge that this approach based on imaging
surrogate indicators cannot be fully applied to NOD.
Another limitation is a lack of power to perform reliable
subgroup analyses based on relevant variables. For
example, given that age is a major risk factor for diabetes,
subgroup analyses looking at narrower age ranges will
provide additional valuable information on potential age
group differences in the risk of statin-induced diabetes.
Large clinical trials need to be conducted to determine
which age group is the most susceptible for developing
statin-induced diabetes or most benefits from the use of
less-diabetogenic statins. With regard to gender, although
there are no direct data on gender differences in the asso-
ciation between statin use and NOD, some previous stud-
ies suggested that diabetogenic potential of statins might
be gender-specific by demonstrating that the baseline level
of adiponectin and the effect of statins on adiponectin
could be different between males and females [56, 57].
Further trials with adequate numbers of males and
females are required to be able to answer the diabetogenic
potential of statins based on gender differences. We
should also acknowledge that the influence of previous
statin use on the study endpoints cannot be completely
excluded, even though we will exclude patients with a
history of statin exposure within 1 month before enroll-
ment and thus will perform stratified randomization
according to the previous use of statins. Finally, patients
receiving some antihypertensive agents with potential to
affect glucose metabolism, such as thiazide-type diuretics,
β-blockers, angiotensin-converting enzyme inhibitors, and
angiotensin receptor blockers, which may be important
covariates, can be included in our study [58]. If these
covariates are not evenly distributed between study groups
despite randomization, we will perform adjusted analysis
in this randomized controlled trial to correct for the
imbalances in covariates.
Conclusions
In the LESS-DM trial, we will investigate the impact of
high-dose pitavastatin on diabetogenicity in comparison
with that of atorvastatin in patients with MetS. In this
Fig. 3 Simplified schematic diagram demonstrating the study hypothesis and associated analyses. We hypothesize that pitavastatin may have a
more favorable influence on glucose metabolism than atorvastatin, potentially mediated by its unique adiponectin-increasing effect. The possible
antidiabetic property of pitavastatin may contribute to improvements in vascular and cardiac functions in patients with metabolic syndrome, a
high-risk group for developing new-onset diabetes mellitus. The Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison
with atorvastatin in patients with Metabolic syndrome (LESS-DM) trial is specifically designed to explore this hypothesis by measuring the change
in hemoglobin A1c (primary endpoint); changes in biochemical markers, including adiponectin; and changes in imaging markers, including
carotid elasticity metrics and left ventricular function parameters, after statin therapy (secondary endpoints). NOD New-onset diabetes mellitus, HbA1c
Hemoglobin A1c, LV Left ventricle
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study, we hypothesize that (1) pitavastatin will have
beneficial effects on the levels of circulating biomarkers
reflecting glucose metabolism; (2) the differences in
diabetogenic properties among the statin types may stem
from differences in their action on adiponectin; and (3)
statins with favorable effects on glucose metabolism will
also relate to improvements in vascular and cardiac
functions (Fig. 3). The results of the LESS-DM trial will
serve as an important step toward a larger clinical out-
come trial testing the statin type-dependent effects on
diabetogenicity and the consequences thereof in patients
with MetS. Moreover, this trial will provide a corner-
stone for statin therapy tailored to specific subgroups at
high risk for NOD, including patients with MetS.
Trial status
This trial is in the recruitment stage (protocol version 2.0,
protocol approval date 7 November 2016, recruitment of
participants start date 2 December 2016, and expected
recruitment completion date 30 November 2019).
Additional files
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOCX 48 kb)
Additional file 2: Supplementary methods for details of imaging
protocols. (DOCX 26 kb)
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